US equities |
SPCX $166.69 ▲+4.86% NVDA $237.00 ▲+1.30% MU $1,064.12 ▼-1.00% TSLA $375.34 ▲+1.28% MSFT $526.62 ▲+1.76% INTC $116.83 ▼-2.10% SNDK $1,716.87 ▼-0.18% META $743.06 ▲+2.06%
FinancialContent

Chimerix, Inc. - Common Stock (NQ:CMRX)

8.540 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Chimerix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings ↗
 
Via Benzinga
News headline image
Dow Falls 150 Points; Oracle Posts Downbeat Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday? ↗
Chimerix plans to submit an NDA for dordaviprone to treat H3 K27M-mutant glioma, with potential U.S. FDA approval targeted for late 2025. 
Via Benzinga
News headline image
CMRX Stock Earnings: Chimerix Misses EPS for Q1 2024 ↗
CMRX stock results show that Chimerix missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Earnings Scheduled For February 29, 2024 ↗
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
News headline image
Preview: Chimerix's Earnings ↗
 
Via Benzinga
News headline image
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
News headline image
CMRX Stock Earnings: Chimerix Meets EPS, Beats Revenue for Q2 2024 ↗
CMRX stock results show that Chimerix met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
From FN Media Group LLC
Via GlobeNewswire
News headline image
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Appoints Marc D. Kozin to Board of Directors
Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy Experience 
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
From Chimerix, Inc.
Via GlobeNewswire
News headline image
Chimerix to Present at TD Cowen 44th Annual Health Care Conference
From Chimerix, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >